FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Sandborn

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
Krisztina B Gecse; Vipul Jairath; Reena Khanna; Mark Löwenberg; Cyriel Y Ponsioen; William J Sandborn; Simon P L Travis; Gijs R van den Brink; Brian G Feagan; Geert D'Haens
Biosimilars in IBD: hope or expectation?
Fernando S Velayos; James G Kahn; William J Sandborn; Brian G Feagan
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab.
Suresh Pola; Elisabeth Evans; Marianne Fahmy; Ann Tipps; William J Sandborn
Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Sandborn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Krisztina B Gecse; Vipul Jairath; Reena Khanna; Mark Löwenberg; Cyriel Y Ponsioen; William J Sandborn; Simon P L Travis; Gijs R van den Brink; Brian G Feagan; Geert D'Haens
Biosimilars in IBD: hope or expectation?
Gut 2013;62(6):803-7.
2013: Fernando S Velayos; James G Kahn; William J Sandborn; Brian G Feagan
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013;11(6):654-66.
2013: Suresh Pola; Elisabeth Evans; Marianne Fahmy; Ann Tipps; William J Sandborn
Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis.
The American journal of gastroenterology 2013;108(5):857-8.
2013: William J Sandborn; Q Zhou; M Castillo; J-F Colombel; G D'Haens; J Panés; S E Plevy; Paul F Pollack; A M Robinson; R B Thakkar
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Current medical research and opinion 2013;29(5):483-93.
2013: Hans H Herfarth; Kim L Isaacs; Jeffry A Katz; Edward V Loftus; Christopher F Martin; William J Sandborn; Robert S Sandler; Bruce E Sands; Joseph A Galanko; Stephen B Hanauer; Dolly Walkup; Ryan B Sartor
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.
Inflammatory bowel diseases 2013;19(5):1073-9.
2013: Emmanouil Sinakos; Felicity Enders; Edward V Loftus; Sunil Samuel; William J Sandborn; Keith D Lindor
Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship.
Inflammatory bowel diseases 2013;19(5):1004-9.
2013: Stefan Schreiber; W Reinisch; A M Robinson; William J Sandborn; Jean-Frédéric Colombel; D W Hommes; B Huang; K G Lomax; Paul F Pollack
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
Journal of Crohn's & colitis 2013;7(3):213-21.
2013: Lee A Denson; Hans H Herfarth; Peter D R Higgins; Jeffrey Hyams; Christian Jobin; Michael Kappelman; Subra Kugathasan; James D Lewis; Edward V Loftus; Millie D Long; Declan F McCole; Dermot P B McGovern; Asma Nusrat; Charles A Parkos; Theresa T Pizarro; Scott Plevy; William J Sandborn; R Balfour Sartor; Corey A Siegel; Thaddeus S Stappenbeck; Gary D Wu; Vincent B Young; Clara Abraham; Edwin F de Zoeten
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda.
Inflammatory bowel diseases 2013;19(4):677-82.
2013: Rami Abboud; Patricia P Kammer; Darrell S Pardi; William J Sandborn; William J Tremaine; Edward V Loftus
Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study.
Inflammatory bowel diseases 2013;19(3):550-3.
2013: William J Sandborn; Simon Travis; David Ballard
Reply: budesonide.
Gastroenterology 2013;144(3):e23-4.
2013: J B Kisiel; Edward V Loftus; Douglas W Mahoney; F T Nazer Hussain; D T Rubin; William J Sandborn; T C Smyrk; W R Taylor; B G Wolff; Tracy Carol Yab; Hongzhi Zou; M M Garrity-Park; S H Itzkowitz; David A Ahlquist
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease.
Alimentary pharmacology & therapeutics 2013;37(5):546-54.
2013: Jennifer L Seminerio; Prabin Thapa; Jean-Frédéric Colombel; Edward V Loftus; William J Sandborn
Infliximab for Crohn's disease: the first 500 patients followed up through 2009.
Digestive diseases and sciences 2013;58(3):797-806.
2013: Marianne Fahmy; Ahmed Shabaik; William J Sandborn
Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy.
Inflammatory bowel diseases 2013;19(4):E57-8.
2013: Nicole M Gentile; Patricia P Kammer; Sahil Khanna; Edward V Loftus; Adil A Abdalla; William A Faubion; William J Sandborn; Thomas C Smyrk; William J Tremaine; Darrell S Pardi
Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study.
The American journal of gastroenterology 2013;108(2):256-9.
2013: William J Sandborn; G Van Assche; D Wolf; M Yang; J D Chao; J-F Colombel; G D'Haens; M Kron; A Lazar; A M Robinson; R Thakkar
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
Alimentary pharmacology & therapeutics 2013;37(2):204-13.
2013: William J Sandborn; Vera S Byers; Hua Mu; Dean A Rutty; Stephan R Targan; Xun Zhang; Tom Tang
Andrographis paniculata extract (HMPL-004) for active ulcerative colitis.
The American journal of gastroenterology 2013;108(1):90-8.
2013: Sunil Samuel; David H Bruining; Piet C de Groen; William A Faubion; William S Harmsen; Sunanda V Kane; Edward V Loftus; Darrell S Pardi; Kenneth W Schroeder; Kelvin T Thia; William J Tremaine; Alan R Zinsmeister; William J Sandborn
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013;11(1):49-54.e1.
2012: Laurent Peyrin-Biroulet; Walter Reinisch; Paul Rutgeerts; Stefan Schreiber; Flávio Steinwurz; Simon Travis; Laurent Beaugerie; Vincent Billioud; Yehuda Chowers; Jean-Frédéric Colombel; Silvio Danese; Geert D'Haens; Brian Feagan; Toshifumi Hibi; Peter Higgins; Edouard Louis; Haruhiko Ogata; Remo Panaccione; Julian Panés; William J Sandborn
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
The American journal of gastroenterology 2012;107(12):1770-6.
2012: Barrett G Levesque; William J Sandborn
Infliximab versus ciclosporin in severe ulcerative colitis.
Lancet 2012;380(9857):1887-8.
2012: Geert D'Haens; Brian Feagan; Richard N Fedorak; Steven Hanauer; Marc Lémann; Jean-Yves Mary; Walter Reinisch; Paul Rutgeerts; William J Sandborn; Frank Carbonnel; Jean-Frédéric Colombel; Silvio Danese
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
Gastroenterology 2012;143(6):1461-9.
2012: Suresh Pola; Sonia Ramamoorthy; Jesus Rivera-Nieves; John T Chang; Michael Docherty; Elisabeth Evans; Marianne Fahmy; Elisabeth McLemore; Derek Patel; Mark A Talamini; William J Sandborn
Strategies for the care of adults hospitalized for active ulcerative colitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012;10(12):1315-1325.e4.
2012: Sunanda V Kane; B Becker; D H Bruining; William A Faubion; K A Hanson; W Scott Harmsen; S Horst; M Moscandrew; B Neis; Darrell S Pardi; William J Sandborn; William J Tremaine; Alan R Zinsmeister; Edward V Loftus
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience.
Inflammatory bowel diseases 2012;18(12):2203-8.
2012: Ingrid Ordás; Daniel C Baumgart; Lars Eckmann; Mark A Talamini; William J Sandborn
Ulcerative colitis.
Lancet 2012;380(9853):1606-19.
2012: Daniel Baumgart; William J Sandborn
Crohn's disease.
Lancet 2012;380(9853):1590-605.
2012: Laurent Peyrin-Biroulet; William J Sandborn; William J Tremaine; Alan R Zinsmeister; W Scott Harmsen; Edward V Loftus
Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004).
The American journal of gastroenterology 2012;107(11):1693-701.
2012: William J Sandborn; Simon Travis; Phil Yeung; Robert Bagin; Theres Gautille; Michael Huang; Richard Jones; Luigi Moro; E David Ballard
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Gastroenterology 2012;143(5):1218-26.e1-2.
2012: Sunil Samuel; Alan R Zinsmeister; Brenda Becker; David H Bruining; Joel G Fletcher; Edward V Loftus; Jayawant N Mandrekar; William J Sandborn
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012;10(11):1253-9.
2012: Ingrid Ordás; Brian G Feagan; William J Sandborn
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012;10(10):1079-87; quiz e85-6.
2012: Gary R Lichtenstein; Anil Londhe; Samiyeh Price; Bruce A Salzberg; Russell D Cohen; Robert H Diamond; Brian G Feagan; Wayne Langholff; William J Sandborn
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
The American journal of gastroenterology 2012;107(9):1409-22.
2012: A B Mohabbat; William J Sandborn; R H Wiesner; Edward V Loftus; D H Bruining
Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Alimentary pharmacology & therapeutics 2012;36(6):569-74.
2012: William J Sandborn; Chinyu Su; Ivana Vranic; Subrata Ghosh; Wojciech Niezychowski; Julian Panes; Samantha Rousell
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
The New England journal of medicine 2012;367(7):616-24.
2012: Bruce E Sands; Ajit Sood; Mary Jean Stempien; Gert A Van Assche; Gourdas Choudhuri; Tom J Creed; Colin M Dayan; Ashwin D Dhanda; Miloš Greguš; Daniel Levitt; William J Sandborn; Christopher S Probert
Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis.
Gastroenterology 2012;143(2):356-64.e1.
2012: Gary R Lichtenstein; Jennifer Montello; Paul Rutgeerts; William J Sandborn; Bruce E Sands; Linda Tang; Marion Blank; Freddy Cornillie; Robert H Diamond; Jean-Frédéric Colombel
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.
The American journal of gastroenterology 2012;107(7):1051-63.
2012: Geert D'Haens; Ian Hodgson; William J Sandborn; Karen Barrett; Paul Streck
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
The American journal of gastroenterology 2012;107(7):1064-77.
2012: William J Sandborn; Bruce E Sands; Stefan Schreiber; Stephan R Targan; Richard Aranda; Brian Bressler; Jean-Frederic Colombel; Karl Geboes; Sheila Gujrathi; Allison Luo; Remo Panaccione; Yun Peng; Paul Rutgeerts; Luisa Salter-Cid; Stephen B Hanauer
Abatacept for Crohn's disease and ulcerative colitis.
Gastroenterology 2012;143(1):62-69.e4.
2012: Lauren E Cipriano; Barrett G Levesque; Edward V Loftus; Gregory S Zaric; William J Sandborn
Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease.
Inflammatory bowel diseases 2012;18(7):1240-8.
2012: Marianne Fahmy; Tissa Hata; Sonia Ramamoorthy; William J Sandborn
Ustekinumab for peristomal pyoderma gangrenosum.
The American journal of gastroenterology 2012;107(5):794-5.
2012: Paul Rutgeerts; William J Sandborn; Gert van Assche; Douglas C Wolf; Karel Geboes; Ashish Kumar; Andreas Lazar; Kathleen G Lomax; Paul F Pollack; Walter Reinisch; Anne Camez; Jean-Frédéric Colombel; Geert D'Haens
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Gastroenterology 2012;142(5):1102-1111.e2.
2012: Alexander C Ford; Stephen B Hanauer; Khurram J Khan; William J Sandborn; Paul Moayyedi
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012;10(5):513-9.
2012: Douglas L Nguyen; William J Sandborn; Brenda Becker; Joel G Fletcher; William S Harmsen; David W Larson; Edward V Loftus; Jay Mandrekar; David H Bruining
Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012;10(4):400-4.
2012: S P L Travis; Bruce R Yacyshyn; Bruce E Sands; Dan Schnell; Maria Abreu; Douglas G Altman; Christian A Bernhardt; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Piotr Krzeski; Marc Lémann; Gary R Lichtenstein; Phillippe R Marteau; Jean-Yves Mary; Walter Reinisch; William J Sandborn
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
Gut 2012;61(4):535-42.
2012: Barrett G Levesque; William J Sandborn
Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease.
Inflammatory bowel diseases 2012;18(4):795-6.
2012: William J Sandborn
Mucosal healing with infliximab: results from the active ulcerative colitis trials.
Gastroenterology & hepatology 2012;8(2):117-9.
2012: Daniel Hommes; Jean-Frédéric Colombel; Paul Emery; Marco Greco; William J Sandborn
Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life.
Journal of Crohn's & colitis 2012;6 Suppl 2():S224-34.
2012: Guillaume P Pineton de Chambrun; William J Sandborn
IBD in 2011: Advances in IBD management--towards a tailored approach.
Nature reviews. Gastroenterology & hepatology 2012;9(2):70-2.
2012: William J Sandborn; Mary Beth Tighe; Gert van Assche; Douglas C Wolf; Jean-Frederic Colombel; Geert D'Haens; Martina Kron; Andreas Lazar; Walter Reinisch; Roopal B Thakkar
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology 2012;142(2):257-65.e1-3.
2012: Laurent Peyrin-Biroulet; William J Sandborn; Gerold Stucki; Yehuda Chowers; Alarcos Cieza; Michaela Coenen; Jean-Frédéric Colombel; Toshifumi Hibi; Nenad Kostanjsek
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.
Gut 2012;61(2):241-7.
2012: William J Sandborn
The future of inflammatory bowel disease therapy: where do we go from here?
Digestive diseases (Basel, Switzerland) 2012;30 Suppl 3():140-4.
2012: Jean-Frédéric Colombel; Edouard Louis; Laurent Peyrin-Biroulet; William J Sandborn; Remo Panaccione
Deep remission: a new concept?
Digestive diseases (Basel, Switzerland) 2012;30 Suppl 3():107-11.
2011: Ingrid Ordás; Brian G Feagan; William J Sandborn
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change.
Gut 2011;60(12):1754-63.
2011: Alexander C Ford; Sunanda V Kane; Khurram J Khan; William J Sandborn; Paul Moayyedi
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
The American journal of gastroenterology 2011;106(12):2070-7; quiz 2078.
2011: William J Sandborn; M Edeline; Stephen B Hanauer; G R Lichtenstein; Michael A Safdi; M Scott Harris
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Alimentary pharmacology & therapeutics 2011;34(7):747-56.
2011: Jean-Frédéric Colombel; Dirk Esser; Brian G Feagan; Stephen B Hanauer; Yinghua Lang; Gary R Lichtenstein; Colleen W Marano; Björn J Oddens; Daniel Present; Walter Reinisch; Paul Rutgeerts; Bruce E Sands; Richard Strauss; Yanxin Wang; William J Sandborn
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Gastroenterology 2011;141(4):1194-201.
2011: Gert van Assche; James D Lewis; Gary R Lichtenstein; Edward V Loftus; Qin Ouyang; Julian Panes; William J Sandborn; Corey A Siegel; Simon P L Travis; Jean-Frederic Colombel
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
The American journal of gastroenterology 2011;106(9):1594-602; quiz 1593, 1603.
2011: William J Sandborn; Stefan Schreiber; Ziad H Younes; Ralph Bloomfield; Geoffroy Coteur; Brian G Feagan; Juan Pablo Guzman; Paul Rutgeerts; Geert R D'Haens
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(8):670-678.e3.
2011: David H Bruining; Eric C Ehman; Jeff L Fidler; William S Harmsen; James E Huprich; Edward V Loftus; Jayawant N Mandrekar; Douglas L Nguyen; William J Sandborn; Hassan A Siddiki; Joel G Fletcher
Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(8):679-683.e1.
2011: Sunil Samuel; Edward V Loftus; William J Sandborn
Henoch-schönlein purpura in an adult mimicking Crohn's disease and pyoderma gangrenosum.
Digestive diseases and sciences 2011;56(7):2205-6.
2011: Barrett G Levesque; William J Sandborn
Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease.
Inflammatory bowel diseases 2011;17(6):1443-4.
2011: Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Gut 2011;60(6):780-7.
2011: Kelvin T Thia; Edward V Loftus; Darrell S Pardi; Sunanda V Kane; William A Faubion; William J Tremaine; Kenneth W Schroeder; Scott W Harmsen; Alan R Zinsmeister; William J Sandborn
Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity.
Inflammatory bowel diseases 2011;17(6):1257-64.
2011: David H Bruining; William J Sandborn
Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(5):395-9.
2011: Nicholas J Talley; Maria Abreu; Jean-Paul Achkar; Charles N Bernstein; Marla C Dubinsky; Stephen B Hanauer; Sunanda V Kane; William J Sandborn; Thomas A Ullman; Paul Moayyedi
An evidence-based systematic review on medical therapies for inflammatory bowel disease.
The American journal of gastroenterology 2011;106 Suppl 1():S2-25; quiz S26.
2011: Alexander C Ford; William J Sandborn; Khurram J Khan; Stephen B Hanauer; Nicholas J Talley; Paul Moayyedi
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
The American journal of gastroenterology 2011;106(4):644-59, quiz 660.
2011: Vincent Billioud; William J Sandborn; Laurent Peyrin-Biroulet
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
The American journal of gastroenterology 2011;106(4):674-84.
2011: William J Sandborn
Why innovation in inflammatory bowel disease drug development will impact your practice.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(3):211-3.
2011: Barrett G Levesque; Karen A Hanson; William J Sandborn
Reversal of multifocal low- and high-grade dysplasia in patients with an ileoanal pouch.
Gastroenterology 2011;140(3):1107-8; author reply 1108-9.
2011: Brian G Feagan; William J Sandborn; D C Wolf; Geoffroy Coteur; O Purcaru; Y Brabant; Paul Rutgeerts
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Alimentary pharmacology & therapeutics 2011;33(5):541-50.
2011: Hassan Siddiki; Joel G Fletcher; Amy K Hara; James M Kofler; Cynthia H McCollough; Jeff L Fidler; Luis Guimaraes; James E Huprich; William J Sandborn; Edward V Loftus; Jayawant N Mandrekar; David H Bruining
Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel.
Inflammatory bowel diseases 2011;17(3):778-86.
2011: Uma Mahadevan; Salvatore Cucchiara; Jeffrey S Hyams; Flavio Steinwurz; F Nuti; Simon P L Travis; William J Sandborn; Jean-Frederio Colombel
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
The American journal of gastroenterology 2011;106(2):214-23; quiz 224.
2011: Geert R D'Haens; Remo Panaccione; Peter Higgins; Severine Vermeire; Miquel Gassull; Yehuda Chowers; Stephen B Hanauer; Hans Herfarth; Daan W Hommes; Michael Kamm; Robert Löfberg; A Quary; Bruce Sands; A Sood; G Watermeyer; G Watermayer; Bret Lashner; Marc Lémann; Scott Plevy; Walter Reinisch; Stefan Schreiber; Corey Siegel; Stephen Targan; M Watanabe; Brian Feagan; William J Sandborn; Jean-Frédéric Colombel; Simon Travis
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
The American journal of gastroenterology 2011;106(2):199-212; quiz 213.
2011: William J Sandborn; Jean-Frédéric Colombel; Stefan Schreiber; Scott Plevy; Paul F Pollack; Anne M Robinson; Jingdong Chao; Parvez Mulani
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.
Inflammatory bowel diseases 2011;17(1):141-51.
2011: Laurent Peyrin-Biroulet; Edward V Loftus; Jean-Frederic Colombel; William J Sandborn
Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts.
Inflammatory bowel diseases 2011;17(1):471-8.
2011: Kelvin Thia; William A Faubion; Edward V Loftus; Tore Persson; Anders Persson; William J Sandborn
Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index.
Inflammatory bowel diseases 2011;17(1):105-11.
2010: Stephen B Hanauer; Asher A Kornbluth; Julie Messick; David T Rubin; William J Sandborn; Bruce E Sands
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents.
Inflammatory bowel diseases 2010;16 Suppl 1():S1-11.
2010: Basil S Nasir; Eric J Dozois; Robert R Cima; John H Pemberton; Bruce G Wolff; William J Sandborn; Edward V Loftus; David W Larson
Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2010;14(12):1859-65; discussion 1865-6.
2010: S Samuel; Edward V Loftus; William J Sandborn
The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis.
Alimentary pharmacology & therapeutics 2010;32(9):1207-9.
2010: William J Sandborn; Jean Frederic Colombel; Matthew Frankel; Daan Hommes; James N Lowder; Lloyd Mayer; Scott Plevy; Pieter Stokkers; Simon Travis; Gert Van Assche; Daniel Baumgart; Stephan R Targan
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
Gut 2010;59(11):1485-92.
2010: Jason M Swoger; Edward V Loftus; William J Tremaine; William A Faubion; Darrell S Pardi; Sunanda V Kane; Karen A Hanson; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients.
Inflammatory bowel diseases 2010;16(11):1912-21.
2010: Kelvin T Thia; William J Sandborn; William S Harmsen; Alan R Zinsmeister; Edward V Loftus
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort.
Gastroenterology 2010;139(4):1147-55.
2010: Stephen B Hanauer; J Panes; J-F Colombel; R Bloomfield; S Schreiber; William J Sandborn
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Alimentary pharmacology & therapeutics 2010;32(3):384-93.
2010: William J Sandborn; Maria Abreu; Geert D'Haens; Jean-Frédéric Colombel; Severine Vermeire; Krassimir Mitchev; Corinne Jamoul; Richard N Fedorak; Martina E Spehlmann; Douglas C Wolf; Scott Lee; Paul Rutgeerts
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2010;8(8):688-695.e2.
2010: William J Sandborn; Stefan Schreiber; Stephen B Hanauer; Jean-Frédéric Colombel; Ralph Bloomfield; Gary R Lichtenstein
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2010;8(8):696-702.e1.
2010: Stefan Schreiber; Jean-Frédéric Colombel; Ralph Bloomfield; Susanna Nikolaus; Jürgen Schölmerich; Julian Panés; William J Sandborn
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
The American journal of gastroenterology 2010;105(7):1574-82.
2010: Megan M Garrity-Park; Edward V Loftus; William J Sandborn; Sandra C Bryant; Thomas C Smyrk
Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer.
The American journal of gastroenterology 2010;105(7):1610-9.
2010: Gary R Lichtenstein; Ole Ø Thomsen; Stefan Schreiber; Ian Craig Lawrance; Stephen B Hanauer; Ralph Bloomfield; William J Sandborn
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2010;8(7):600-9.
2010: Remo Panaccione; J-F Colombel; William J Sandborn; Paul Rutgeerts; G R D'Haens; A M Robinson; J Chao; P M Mulani; P F Pollack
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
Alimentary pharmacology & therapeutics 2010;31(12):1296-309.
2010: OUSSALAH Abderrahim; Jean-Baptiste Chevaux; Renaud Fay; William J Sandborn; Marc-André Bigard; Laurent Peyrin-Biroulet
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
The American journal of gastroenterology 2010;105(5):1142-9.
2010: Waqqas Afif; Edward V Loftus; William A Faubion; Sunanda V Kane; David H Bruining; Karen A Hanson; William J Sandborn
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.
The American journal of gastroenterology 2010;105(5):1133-9.
2010: Jean-Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Infliximab, azathioprine, or combination therapy for Crohn's disease.
The New England journal of medicine 2010;362(15):1383-95.
2010: Severine Vermeire; Stefan Schreiber; William J Sandborn; Cécile Dubois; Paul Rutgeerts
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2010;8(4):357-63.
2010: William J Sandborn; Joshua Korzenik; Bret Lashner; Jonathan A Leighton; Uma Mahadevan; James F Marion; Michael A Safdi; Charles A Sninsky; Raman M Patel; Keith A Friedenberg; Preston Dunnmon; David Ramsey; Sunanda Kane
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Gastroenterology 2010;138(4):1286-96, 1296.e1-3.
2010: Daniel Baumgart; Stephan R Targan; Axel U Dignass; Lloyd Mayer; Gert van Assche; Daan W Hommes; Stephen B Hanauer; Uma Mahadevan; Walter Reinisch; Scott Plevy; Bruce A Salzberg; Alan L Buchman; Grigor M Mechkov; Zahariy A Krastev; James N Lowder; Matthew B Frankel; William J Sandborn
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
Inflammatory bowel diseases 2010;16(4):620-9.
2010: Laurent Peyrin-Biroulet; Edward V Loftus; Jean-Frederic Colombel; William J Sandborn
Early Crohn disease: a proposed definition for use in disease-modification trials.
Gut 2010;59(2):141-7.
2010: Laurent Peyrin-Biroulet; Edward V Loftus; Jean-Frederic Colombel; William J Sandborn
The natural history of adult Crohn's disease in population-based cohorts.
The American journal of gastroenterology 2010;105(2):289-97.
2010: Luís S Guimarães; Jeff L Fidler; Joel G Fletcher; David H Bruining; James E Huprich; Hassan Siddiki; William J Sandborn; Edward V Loftus; Darrell S Pardi; Cynthia H McCollough
Assessment of appropriateness of indications for CT enterography in younger patients.
Inflammatory bowel diseases 2010;16(2):226-32.
2010: William J Sandborn
State-of-the-art: Immunosuppression and biologic therapy.
Digestive diseases (Basel, Switzerland) 2010;28(3):536-42.
2010: Stefan D Holubar; Robert R Cima; William J Sandborn; Darrell S Pardi
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Cochrane database of systematic reviews (Online) 2010;(6):CD001176.
2010: Kishore Malireddy; David W Larson; William J Sandborn; Edward V Loftus; William A Faubion; Darrell S Pardi; Rui Qin; Rachel E Gullerud; Robert R Cima; Bruce Wolff; Eric J Dozois
Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease.
Archives of surgery (Chicago, Ill. : 1960) 2010;145(1):42-7.
2010: Laurent Peyrin-Biroulet; Alarcos Cieza; William J Sandborn; Nenad Kostanjsek; Michael A Kamm; Toshifumi Hibi; Marc Lémann; Gerold Stucki; Jean-Frédéric Colombel
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health.
Inflammatory bowel diseases 2010;16(1):15-22.
2009: William J Sandborn; Jaroslaw Regula; Brian G Feagan; Elena Belousova; Njegica Jojic; Milan Lukas; Bruce Yacyshyn; Piotr Krzeski; Chyon-Hwa Yeh; Christi A Messer; Stephen B Hanauer
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Gastroenterology 2009;137(6):1934-43.e1-3.
2009: N Manabe; Filippo Cremonini; Michael Camilleri; William J Sandborn; Duane D Burton
Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers.
Alimentary pharmacology & therapeutics 2009;30(9):930-6.
2009: Gary P Toedter; Marion Blank; Yinghua Lang; Dion Chen; William J Sandborn; Willem J S de Villiers
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease.
The American journal of gastroenterology 2009;104(11):2768-73.
2009: Geert R D'Haens; Richard Fedorak; Marc Lémann; Brian G Feagan; Michael A Kamm; Jacques Cosnes; Paul J Rutgeerts; Philippe Marteau; Simon Travis; Jürgen Schölmerich; Steven Hanauer; William J Sandborn
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
Inflammatory bowel diseases 2009;15(10):1599-604.
2009: William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel H Present; Bruce Sands; Jean-Frédéric Colombel
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Gastroenterology 2009;137(4):1250-60; quiz 1520.
2009: Josh Marehbian; H Michael Arrighi; Steve Hass; Haijun Tian; William J Sandborn
Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
The American journal of gastroenterology 2009;104(10):2524-33.
2009: Laurent Peyrin-Biroulet; Jean-Frederic Colombel; William J Sandborn
Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2009;7(10):1139.
2009: Jean-Frédéric Colombel; William J Sandborn; Remo Panaccione; Anne M Robinson; Winnie Lau; Ju Li; Alexandra T Cardoso
Adalimumab safety in global clinical trials of patients with Crohn's disease.
Inflammatory bowel diseases 2009;15(9):1308-19.
2009: Waqqas Afif; Jonathan A Leighton; Stephen B Hanauer; Edward V Loftus; William A Faubion; Darrell S Pardi; William J Tremaine; Sunanda V Kane; David H Bruining; Russell D Cohen; David T Rubin; Karen A Hanson; William J Sandborn
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
Inflammatory bowel diseases 2009;15(9):1302-7.
2009: M M Garrity-Park; Edward V Loftus; William J Sandborn; Sandra C Bryant; Thomas C Smyrk
MHC Class II alleles in ulcerative colitis-associated colorectal cancer.
Gut 2009;58(9):1226-33.
2009: Karthik Ravi; Suresh T Chari; Santhi Swaroop Vege; William J Sandborn; Thomas C Smyrk; Edward V Loftus
Inflammatory bowel disease in the setting of autoimmune pancreatitis.
Inflammatory bowel diseases 2009;15(9):1326-30.
2009: Fernando S Velayos; William J Sandborn
Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride?
The American journal of gastroenterology 2009;104(8):2097-9.
2009: Gary R Lichtenstein; Robert H Diamond; C L Wagner; A A Fasanmade; A D Olson; C W Marano; J Johanns; Y Lang; William J Sandborn
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Alimentary pharmacology & therapeutics 2009;30(3):210-26.
2009: Hassan A Siddiki; Jeff L Fidler; Joel G Fletcher; Sharon S Burton; James E Huprich; David M Hough; C Daniel Johnson; David H Bruining; Edward V Loftus; William J Sandborn; Darrell S Pardi; Jayawant N Mandrekar
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease.
AJR. American journal of roentgenology 2009;193(1):113-21.
2009: Jean-Frédéric Colombel; D A Schwartz; William J Sandborn; M A Kamm; Geert D'Haens; Paul Rutgeerts; Robert Enns; Remo Panaccione; Stefan Schreiber; J Li; J D Kent; K G Lomax; Paul F Pollack
Adalimumab for the treatment of fistulas in patients with Crohn's disease.
Gut 2009;58(7):940-8.
2009: Fargol Booya; Salma Akram; Joel G Fletcher; James E Huprich; C Daniel Johnson; Jeff L Fidler; John M Barlow; Craig A Solem; William J Sandborn; Edward V Loftus
CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings.
Abdominal imaging 2009;34(4):467-75.
2009: Maria Abreu; Christian von Tirpitz; Robert Hardi; Martin Kaatz; Gert Van Assche; Paul Rutgeerts; Emil Bisaccia; Sergi Goerdt; Stephen Hanauer; Robert Knobler; Peter Mannon; Lloyd Mayer; Thomas Ochsenkuhn; William J Sandborn; Dennis Parenti; Kevin Lee; Walter Reinisch
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.
Inflammatory bowel diseases 2009;15(6):829-36.
2009: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Michael A Kamm; Andrew P Yu; Eric Q Wu; Paul F Pollack; Kathleen G Lomax; Jingdong Chao; Parvez Mulani
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
The American journal of gastroenterology 2009;104(5):1170-9.
2009: Karen A Hanson; Edward V Loftus; W Scott Harmsen; Nancy N Diehl; Alan R Zinsmeister; William J Sandborn
Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study.
Inflammatory bowel diseases 2009;15(5):772-7.
2009: Daniel Baumgart; James N Lowder; Stephan R Targan; William J Sandborn; Matthew B Frankel
Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease.
The American journal of gastroenterology 2009;104(4):868-76.
2009: Edward V Loftus; Howard S Friedman; David J Delgado; William J Sandborn
Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States.
Inflammatory bowel diseases 2009;15(4):566-75.
2009: Gary R Lichtenstein; Stephen B Hanauer; William J Sandborn
Management of Crohn's disease in adults.
The American journal of gastroenterology 2009;104(2):465-83; quiz 464, 484.
2009: William J Sandborn
How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease.
Digestive diseases (Basel, Switzerland) 2009;27 Suppl 1():80-4.
2009: William J Sandborn
The future of inflammatory bowel disease care.
Reviews in gastroenterological disorders 2009;9(3):E69-77.
2009: Jennifer Jones; Li-Sheng Chen; Linnea Baudhuin; Sandra Peterson; W Scott Harmsen; Alan R Zinsmeister; Joseph McConnell; William J Sandborn
Relationships between C-reactive protein concentration and genotype in healthy volunteers.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(1):20-5.
2008: David H Bruining; Hassan A Siddiki; Joel G Fletcher; William J Tremaine; William J Sandborn; Edward V Loftus
Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography.
Inflammatory bowel diseases 2008;14(12):1701-6.
2008: Timothy C Wang; Fabio Cominelli; David E Fleischer; James M Gordon; Robert M Glickman; David Limsui; Kenneth R McQuaid; Marshall Montrose; Pankaj J Pasricha; Don W Powell; William A Rowe; William J Sandborn; Andrea Todisco
AGA Institute Future Trends Committee report: the future of gastroenterology training programs in the United States.
Gastroenterology 2008;135(5):1764-89.e2.
2008: William J Sandborn
Current directions in IBD therapy: what goals are feasible with biological modifiers?
Gastroenterology 2008;135(5):1442-7.
2008: Brian G Feagan; Remo Panaccione; William J Sandborn; Geert D'Haens; Stefan Schreiber; Paul J Rutgeerts; Edward V Loftus; Kathleen G Lomax; Andrew P Yu; Eric Q Wu; Jingdong Chao; Parvez Mulani
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
Gastroenterology 2008;135(5):1493-9.
2008: Jennifer Jones; Edward V Loftus; Remo Panaccione; Li-Sheng Chen; Sandra Peterson; Joseph McConnell; Linnea Baudhuin; Karen Hanson; Brian G Feagan; Scott W Harmsen; Alan R Zinsmeister; Emelie Helou; William J Sandborn
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008;6(11):1218-24.
2008: William J Sandborn
Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience.
Inflammatory bowel diseases 2008;14 Suppl 2():S232-3.
2008: William J Sandborn; Brian G Feagan; Richard N Fedorak; Ellen Scherl; Mark R Fleisher; Seymour Katz; Jewel Johanns; Marion Blank; Paul Rutgeerts
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Gastroenterology 2008;135(4):1130-41.
2008: Remo Panaccione; P Rutgeerts; William J Sandborn; Brian G Feagan; Stefan Schreiber; S Ghosh
Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.
Alimentary pharmacology & therapeutics 2008;28(6):674-88.
2008: Bruce Sands; William J Sandborn; Brian Feagan; Robert Löfberg; Toshifumi Hibi; Tao Wang; Lisa-Marie Gustofson; Cindy J Wong; Margaret K Vandervoort; Stephen Hanauer
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.
Gastroenterology 2008;135(2):400-9.
2008: Joanna M Peloquin; Darrell S Pardi; William J Sandborn; Joel G Fletcher; Cynthia H McCollough; Beth A Schueler; James A Kofler; Felicity T B Enders; Sara J Achenbach; Edward V Loftus
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease.
The American journal of gastroenterology 2008;103(8):2015-22.
2008: Craig A Solem; Edward V Loftus; Joel G Fletcher; Todd H Baron; Christopher J Gostout; Bret T Petersen; William J Tremaine; Laurence J Egan; William A Faubion; Kenneth W Schroeder; Darrell S Pardi; Karen A Hanson; Debra A Jewell; John M Barlow; Jeff L Fidler; James E Huprich; C Daniel Johnson; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial.
Gastrointestinal endoscopy 2008;68(2):255-66.
2008: Laurent Peyrin-Biroulet; Pierre Desreumaux; William J Sandborn; Jean-Frédéric Colombel
Crohn's disease: beyond antagonists of tumour necrosis factor.
Lancet 2008;372(9632):67-81.
2008: William J Sandborn
Certolizumab Pegol for Moderate-to-Severe Crohn's Disease.
Gastroenterology & hepatology 2008;4(7):467-8.
2008: Edward V Loftus; David J Delgado; Howard S Friedman; William J Sandborn
Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States.
The American journal of gastroenterology 2008;103(7):1737-45.
2008: Laurent Peyrin-Biroulet; Pierre Deltenre; Nicolas de Suray; Julien Branche; William J Sandborn; Jean-Frédéric Colombel
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008;6(6):644-53.
2008: Gary R Lichtenstein; Michael A Kamm; William J Sandborn; Andrew Lyne; Raymond E Joseph
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Alimentary pharmacology & therapeutics 2008;27(11):1094-102.
2008: Karel Geboes; Jean-Frédéric Colombel; Adrian Greenstein; Derek P Jewell; William J Sandborn; Morten H Vatn; Bryan Warren; Robert H Riddell
Indeterminate colitis: a review of the concept--what's in a name?
Inflammatory bowel diseases 2008;14(6):850-7.
2008: Brian G Feagan; William J Sandborn; Ulrich Mittmann; Simon Bar-Meir; Geert D'Haens; Marc Bradette; Albert Cohen; Chrystian Dallaire; Terry P Ponich; J W D McDonald; Xavier Hébuterne; Pierre Paré; Pavel Klvana; Yaron Niv; Sandro Ardizzone; Olga Alexeeva; Alaa Rostom; Gediminas Kiudelis; Johannes Spleiss; Denise Gilgen; Margaret K Vandervoort; Cindy J Wong; Guang Yong Zou; Allan Donner; Paul Rutgeerts
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.
JAMA : the journal of the American Medical Association 2008;299(14):1690-7.
2008: Murat Toruner; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; Robert Orenstein; William J Sandborn; Jean-Frédéric Colombel; Laurence J Egan
Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Gastroenterology 2008;134(4):929-36.
2008: William J Sandborn
Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Journal of clinical gastroenterology 2008;42(4):338-44.
2008: William J Sandborn
Initial combination therapy in early Crohn's disease.
Lancet 2008;371(9613):635-6.
2008: Megan M Garrity-Park; Edward V Loftus; Sandra C Bryant; William J Sandborn; Thomas C Smyrk
Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer.
The American journal of gastroenterology 2008;103(2):407-15.
2007: Fernando S Velayos; William J Sandborn
Positioning biologic therapy for Crohn's disease and ulcerative colitis.
Current gastroenterology reports 2007;9(6):521-7.
2007: S B Hanauer; William J Sandborn; Chrystian Dallaire; A Archambault; B Yacyshyn; C Yeh; N Smith-Hall
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2007;21(12):827-34.
2007: Brian G Feagan; William J Sandborn; Steven Hass; Timothy Niecko; Jeffrey White
Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
The American journal of gastroenterology 2007;102(12):2737-46.
2007: William J Sandborn; Brian G Feagan; Gary R Lichtenstein
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Alimentary pharmacology & therapeutics 2007;26(7):987-1003.
2007: Uma Mahadevan; William J Sandborn; De-Kun Li; Shahbaz Hakimian; Sunanda Kane; Douglas A Corley
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California.
Gastroenterology 2007;133(4):1106-12.
2007: Robert R Cima; Kari J Anderson; David W Larson; Eric J Dozois; Imran Hassan; William J Sandborn; Edward V Loftus; John H Pemberton
Internet use by patients in an inflammatory bowel disease specialty clinic.
Inflammatory bowel diseases 2007;13(10):1266-70.
2007: Kim L Isaacs; Robert S Sandler; Maria Abreu; Michael F Picco; Stephen B Hanauer; Stephen Bickston; Daniel H Present; Francis A Farraye; Douglas Wolf; William J Sandborn
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
Inflammatory bowel diseases 2007;13(10):1250-5.
2007: Trevor A Winter; William J Sandborn; Willem Js de Villiers; Stefan Schreiber
Treatment of Crohn's disease with certolizumab pegol.
Expert review of clinical immunology 2007;3(5):683-94.
2007: Walter Reinisch; William J Sandborn; Mohan Bala; Songkai Yan; Brian G Feagan; Paul Rutgeerts; Graham Radford-Smith; Stephen Xu; Debra Eisenberg; Allan Olson; Jean-Frédéric Colombel
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
Inflammatory bowel diseases 2007;13(9):1135-40.
2007: William J Sandborn; Stephen B Hanauer; Paul Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; Remo Panaccione; D Wolf; J D Kent; B Bittle; J Li; Paul F Pollack
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Gut 2007;56(9):1232-9.
2007: Stefan Schreiber; Mani Khaliq-Kareemi; Ian Craig Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn
Maintenance therapy with certolizumab pegol for Crohn's disease.
The New England journal of medicine 2007;357(3):239-50.
2007: William J Sandborn; Brian G Feagan; Simeon Stoinov; Pieter J Honiball; Paul Rutgeerts; David Mason; Ralph Bloomfield; Stefan Schreiber
Certolizumab pegol for the treatment of Crohn's disease.
The New England journal of medicine 2007;357(3):228-38.
2007: William J Sandborn; Michael A Kamm; Gary R Lichtenstein; Andrew Lyne; Todd Butler; Raymond E Joseph
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Alimentary pharmacology & therapeutics 2007;26(2):205-15.
2007: Michael Clark; Jean-Frédéric Colombel; Brian C Feagan; Richard N Fedorak; Stephen B Hanauer; Michael A Kamm; Lloyd Mayer; Carol Regueiro; Paul Rutgeerts; William J Sandborn; Bruce Sands; Stefan Schreiber; Stephan R Targan; Simon Travis; Severine Vermeire
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
Gastroenterology 2007;133(1):312-39.
2007: William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Jean-Frédéric Colombel; Remo Panaccione; Geert D'Haens; Ju Li; Marie R Rosenfeld; Jeffrey D Kent; Paul F Pollack
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Annals of internal medicine 2007;146(12):829-38.
2007: William J Tremaine; L J Timmons; Edward V Loftus; Darrell S Pardi; William J Sandborn; W S Harmsen; Prabin Thapa; Alan R Zinsmeister
Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease.
Alimentary pharmacology & therapeutics 2007;25(12):1435-41.
2007: Michael Camilleri; William J Sandborn; Joseph C Kolars; Joseph A Murray; John J Poterucha; Lewis Roberts; Frank A Sinicrope; Kenneth K Wang
A moveable feast.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2007;5(6):646-7.
2007: Daniel Baumgart; William J Sandborn
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Lancet 2007;369(9573):1641-57.
2007: Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Gastroenterology 2007;132(5):1672-83.
2007: Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; W Scott Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.
Journal of the American College of Surgeons 2007;204(5):956-62; discussion 962-3.
2007: Brian G Feagan; Walter Reinisch; Paul Rutgeerts; William J Sandborn; Songkai Yan; Debra Eisenberg; Mohan Bala; Jewel Johanns; Allan Olson; Stephen B Hanauer
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
The American journal of gastroenterology 2007;102(4):794-802.
2007: Tine Jess; Edward V Loftus; Fernando S Velayos; Karen Vanessa Winther; William J Tremaine; Alan R Zinsmeister; W Scott Harmsen; Ebbe Langholz; Vibeke Binder; Pia Munkholm; William J Sandborn
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.
The American journal of gastroenterology 2007;102(4):829-36.
2007: Darrell S Pardi; Edward V Loftus; Thomas C Smyrk; Patricia P Kammer; William J Tremaine; Cathy D Schleck; W Scott Harmsen; Alan R Zinsmeister; Joseph L Melton; William J Sandborn
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota.
Gut 2007;56(4):504-8.
2007: Conor G Loftus; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; Joseph L Melton; William J Sandborn
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.
Inflammatory bowel diseases 2007;13(3):254-61.
2007: Geert D'Haens; William J Sandborn; Brian G Feagan; Karel Geboes; Stephen B Hanauer; E Jan Irvine; Marc Lémann; Philippe Marteau; Paul Rutgeerts; Jurgen Schölmerich; Lloyd R Sutherland
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
Gastroenterology 2007;132(2):763-86.
2007: David Limsui; Darrell S Pardi; Michael Camilleri; Edward V Loftus; Patricia P Kammer; William J Tremaine; William J Sandborn
Symptomatic overlap between irritable bowel syndrome and microscopic colitis.
Inflammatory bowel diseases 2007;13(2):175-81.
2007: William J Sandborn
Step-up versus top-down therapy in the treatment of ulcerative colitis.
Gastroenterology & hepatology 2007;3(1):16-7.
2007: William J Sandborn
A new treatment option for ulcerative colitis.
Reviews in gastroenterological disorders 2007;7(2):106-7.
2007: William J Sandborn
Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments.
Reviews in gastroenterological disorders 2007;7 Suppl 2():S23-35.
2007: William J Sandborn
Clinical perspectives in Crohn's disease: now and in the future. Introduction.
Reviews in gastroenterological disorders 2007;7 Suppl 2():S1-2.
2007: Stephen B Hanauer; William J Sandborn
Refining the role of TNF antagonists for Crohn's disease. Introduction.
Reviews in gastroenterological disorders 2007;7 Suppl 1():S1-2.
2007: Michael A Kamm; William J Sandborn; Miguel Gassull; Stefan Schreiber; Lechoslaw Jackowski; Todd Butler; Andrew Lyne; David Stephenson; Mary Palmen; Raymond E Joseph
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Gastroenterology 2007;132(1):66-75; quiz 432-3.
2007: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Gastroenterology 2007;132(1):52-65.
2007: Gary R Lichtenstein; Michael A Kamm; Prabhakar Boddu; Natalya Gubergrits; Andrew Lyne; Todd Butler; Kirstin Lees; Raymond E Joseph; William J Sandborn
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2007;5(1):95-102.
2006: Jeanne Tung; Edward V Loftus; Deborah K Freese; Mounif El-Youssef; Alan R Zinsmeister; Joseph L Melton; W Scott Harmsen; William J Sandborn; William A Faubion
A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis.
Inflammatory bowel diseases 2006;12(12):1093-100.
2006: Fargol Booya; Joel G Fletcher; James E Huprich; John M Barlow; C Daniel Johnson; Jeff L Fidler; Craig A Solem; William J Sandborn; Edward V Loftus; W Scott Harmsen
Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography.
Radiology 2006;241(3):787-95.
2006: J F Colombel; Craig A Solem; William J Sandborn; Fargol Booya; E V Loftus; W Scott Harmsen; A R Zinsmeister; Kale D Bodily; Joel G Fletcher
Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein.
Gut 2006;55(11):1561-7.
2006: Gert van Assche; William J Sandborn; Brian G Feagan; Bruce A Salzberg; D Silvers; P S Monroe; W M Pandak; F H Anderson; John Valentine; G E Wild; D J Geenen; R Sprague; S R Targan; Paul Rutgeerts; V Vexler; D Young; R S Shames
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Gut 2006;55(11):1568-74.
2006: Tine Jess; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; William J Tremaine; Joseph L Melton; Pia Munkholm; William J Sandborn
Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004.
Gut 2006;55(9):1248-54.
2006: Bruce Sands; Karl M Kilgore; Richard S Bloomfeld; William J Sandborn
Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice.
Journal of clinical gastroenterology 2006;40(7):587-91.
2006: Aran W Laing; Darrell S Pardi; Edward V Loftus; Thomas C Smyrk; Patricia P Kammer; William J Tremaine; Cathy D Schleck; W Scott Harmsen; Alan R Zinsmeister; Joseph L Melton; William J Sandborn
Microscopic colitis is not associated with cholecystectomy or appendectomy.
Inflammatory bowel diseases 2006;12(8):708-11.
2006: Tine Jess; Edward V Loftus; Fernando S Velayos; W Scott Harmsen; Alan R Zinsmeister; Thomas C Smyrk; William J Tremaine; Joseph L Melton; Pia Munkholm; William J Sandborn
Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota.
Inflammatory bowel diseases 2006;12(8):669-76.
2006: Bruce Sands; William J Sandborn; Douglas C Wolf; Seymour Katz; Michael A Safdi; David A Schwartz; Stephen B Hanauer
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.
Journal of clinical gastroenterology 2006;40(6):482-9.
2006: Paul Rutgeerts; William J Sandborn; Richard N Fedorak; Daniel Rachmilewitz; Dino Tarabar; Peter Gibson; Ole Haagen Nielsen; Gary Wild; Stefan Schreiber; Claudia Pena Rossi; Monia Zignani
Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(7):888-93.
2006: Fernando S Velayos; Edward V Loftus; Tine Jess; W Scott Harmsen; John Bida; Alan R Zinsmeister; William J Tremaine; William J Sandborn
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.
Gastroenterology 2006;130(7):1941-9.
2006: Stefan Schreiber; William J Sandborn
CLASSIC-I study the efficacy of adalimumab.
Gastroenterology 2006;130(6):1929-30.
2006: Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(5):621-30.
2006: Gary R Lichtenstein; Allan Olson; Suzanne Travers; Robert H Diamond; Donny M Chen; Michelle L Pritchard; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Stephen B Hanauer; William J Sandborn
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
The American journal of gastroenterology 2006;101(5):1030-8.
2006: William J Sandborn
What's new: innovative concepts in inflammatory bowel disease.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2006;8 Suppl 1():3-9.
2006: Darrell S Pardi; William J Sandborn
Systematic review: the management of pouchitis.
Alimentary pharmacology & therapeutics 2006;23(8):1087-96.
2006: Tine Jess; Edward V Loftus; Fernando S Velayos; W Scott Harmsen; Alan R Zinsmeister; Thomas C Smyrk; Cathy D Schleck; William J Tremaine; Joseph L Melton; Pia Munkholm; William J Sandborn
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota.
Gastroenterology 2006;130(4):1039-46.
2006: Brian G Feagan; William J Sandborn; Gary R Lichtenstein; Graham Radford-Smith; J Patel; A Innes
CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Alimentary pharmacology & therapeutics 2006;23(5):617-28.
2006: Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul F Pollack
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Gastroenterology 2006;130(2):323-33; quiz 591.
2006: William J Sandborn; William F Stenson; Jørn Brynskov; Robin G Lorenz; Gina M Steidle; Jeffery L Robbins; Jeffery D Kent; Bradley J Bloom
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(2):203-11.
2006: Kale D Bodily; Joel G Fletcher; Craig A Solem; C Daniel Johnson; Jeff L Fidler; John M Barlow; Michael R Bruesewitz; Cynthia H McCollough; William J Sandborn; Edward V Loftus; W Scott Harmsen; Brian S Crownhart
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation.
Radiology 2006;238(2):505-16.
2006: Stephen B Hanauer; William J Sandborn; Nimish Vakil; Philip O Katz; Nicholas J Talley; Douglas K Rex; Robert H Hawes; Nalini M Guda; Martin L Freeman; Emmet B Keeffe; Luis Balart
Best of DDW 2006.
Reviews in gastroenterological disorders 2006;6(3):153-89.
2006: William J Sandborn
Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Reviews in gastroenterological disorders 2006;6(2):97-105.
2006: William J Sandborn
Preliminary data on the use of apheresis in inflammatory bowel disease.
Inflammatory bowel diseases 2006;12 Suppl 1():S15-21.
2006: Ashish Chopra; Darrell S Pardi; Edward V Loftus; William J Tremaine; Laurence J Egan; William A Faubion; Karen A Hanson; Therese A Johnson; William J Sandborn
Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice.
Inflammatory bowel diseases 2006;12(1):29-32.
2005: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel H Present; Bruce Sands; Jean-Frédéric Colombel
Infliximab for induction and maintenance therapy for ulcerative colitis.
The New England journal of medicine 2005;353(23):2462-76.
2005: Laurence J Egan; William J Sandborn
Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis.
Current gastroenterology reports 2005;7(6):485-91.
2005: Picha Moolsintong; Edward V Loftus; Suresh T Chari; Laurence J Egan; William J Tremaine; William J Sandborn
Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes.
Inflammatory bowel diseases 2005;11(12):1080-4.
2005: William J Sandborn; Jean-Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian Craig Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan R Targan; Sander J H van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Natalizumab induction and maintenance therapy for Crohn's disease.
The New England journal of medicine 2005;353(18):1912-25.
2005: Stephen B Hanauer; William J Sandborn; Asher Kornbluth; Seymour Katz; Michael A Safdi; Scott Woogen; Gino Regalli; Chyon Yeh; Nancy Smith-Hall; Funmilay Ajayi
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
The American journal of gastroenterology 2005;100(11):2478-85.
2005: Kim L Isaacs; James D Lewis; William J Sandborn; Bruce Sands; Stephan R Targan
State of the art: IBD therapy and clinical trials in IBD.
Inflammatory bowel diseases 2005;11 Suppl 1():S3-12.
2005: Bruce Sands; Maria Abreu; George D Ferry; Anne M Griffiths; Stephen B Hanauer; Kim L Isaacs; James D Lewis; William J Sandborn; A Hillary Steinhart
Design issues and outcomes in IBD clinical trials.
Inflammatory bowel diseases 2005;11 Suppl 1():S22-8.
2005: Marla C Dubinsky; Eileen Reyes; Joshua J Ofman; Chiun-Fang Chiou; Sally Wade; William J Sandborn
A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
The American journal of gastroenterology 2005;100(10):2239-47.
2005: David W Larson; Eric J Dozois; William J Sandborn; Robert R Cima
Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis.
Surgical endoscopy 2005;19(9):1284-7.
2005: William J Sandborn; Robert Löfberg; Brian G Feagan; Stephen B Hanauer; Massimo Campieri; Gordon R Greenberg
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
The American journal of gastroenterology 2005;100(8):1780-7.
2005: Craig A Solem; Edward V Loftus; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
Inflammatory bowel diseases 2005;11(8):707-12.
2005: Murat Toruner; Gavin C Harewood; Edward V Loftus; William J Sandborn; William J Tremaine; William A Faubion; Kenneth W Schroeder; Laurence J Egan
Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease.
Inflammatory bowel diseases 2005;11(5):428-34.
2005: Uma Mahadevan; Sunanda Kane; William J Sandborn; R D Cohen; K Hanson; Jonathan P Terdiman; David Binion
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
Alimentary pharmacology & therapeutics 2005;21(6):733-8.
2005: Darrell S Pardi; William J Sandborn
Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?
Gut 2005;54(3):321-2.
2005: Brian G Feagan; William J Sandborn; J P Baker; F Cominelli; L R Sutherland; C O Elson; Bruce A Salzberg; A Archambault; C N Bernstein; Gary R Lichtenstein; P K Heath; S Cameron; Stephen B Hanauer
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Alimentary pharmacology & therapeutics 2005;21(4):373-84.
2005: Stephen B Hanauer; William J Sandborn; A Persson; Tore Persson
Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Alimentary pharmacology & therapeutics 2005;21(4):363-71.
2005: Carlton W Thomas; Gennett M Myhre; Renee C Tschumper; Raghavakaimal Sreekumar; Diane F Jelinek; David J McKean; James J Lipsky; William J Sandborn; Laurence J Egan
Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines.
The Journal of pharmacology and experimental therapeutics 2005;312(2):537-45.
2005: William J Sandborn
Inflammatory bowel disease: a new combination therapy for pouchitis.
Reviews in gastroenterological disorders 2005;5(2):110.
2005: William J Sandborn
New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
Reviews in gastroenterological disorders 2005;5(1):10-8.
2005: Edward V Loftus; Gavin C Harewood; Conor G Loftus; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister; D A Jewell; William J Sandborn
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.
Gut 2005;54(1):91-6.
2004: William J Sandborn; Darrell S Pardi
Clinical management of pouchitis.
Gastroenterology 2004;127(6):1809-14.
2004: Peter J Mannon; Ivan J Fuss; Lloyd Mayer; Charles O Elson; William J Sandborn; Daniel H Present; Ben J. Dolin; Nancy Goodman; Catherine Groden; Ronald L Hornung; Martha Quezado; Zhiqiong Yang; Markus F Neurath; Jochen Salfeld; Geertruida M Veldman; Ullrich Schwertschlag; Warren Strober
Anti-interleukin-12 antibody for active Crohn's disease.
The New England journal of medicine 2004;351(20):2069-79.
2004: William J Sandborn; Stephen B Hanauer; Edward V Loftus; William J Tremaine; Sunanda Kane; Russell Cohen; Karen Hanson; Therese Johnson; Debra Schmitt; Resa Jeche
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
The American journal of gastroenterology 2004;99(10):1984-9.
2004: William J Sandborn; Brian G Feagan; Graham Radford-Smith; A Kovacs; R Enns; A Innes; J Patel
CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
Gut 2004;53(10):1485-93.
2004: Fernando S Velayos; William J Sandborn
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.
Inflammatory bowel diseases 2004;10(5):657-60.
2004: William J Sandborn; Brian G Feagan
The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain.
Gastroenterology 2004;127(3):990-3.
2004: Remo Panaccione; William J Sandborn
Medical therapy of Crohn disease.
Current opinion in gastroenterology 2004;20(4):351-9.
2004: Conor G Loftus; Laurence J Egan; William J Sandborn
Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease.
Gastroenterology clinics of North America 2004;33(2):141-69, vii.
2004: William J Sandborn; Edward V Loftus
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.
Gut 2004;53(6):780-2.
2004: William J Sandborn; Stephen B Hanauer; A Buch
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Alimentary pharmacology & therapeutics 2004;19(10):1089-98.
2004: Elena Ricart; Remo Panaccione; Edward V Loftus; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study.
Inflammatory bowel diseases 2004;10(3):207-14.
2004: Laurence J Egan; William J Sandborn
Advances in the treatment of Crohn's disease.
Gastroenterology 2004;126(6):1574-81.
2004: Jean-Frédéric Colombel; Edward V Loftus; William J Tremaine; John H Pemberton; Bruce G Wolff; Tonia M Young-Fadok; W Scott Harmsen; Cathy D Schleck; William J Sandborn
Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
The American journal of gastroenterology 2004;99(5):878-83.
2004: Gregory M Matzke; Ajaipal S Kang; Eric J Dozois; William J Sandborn
Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: an alternative to pouch excision.
Diseases of the colon and rectum 2004;47(5):782-6.
2004: William J Sandborn
Pharmacogenomics and IBD: TPMT and thiopurines.
Inflammatory bowel diseases 2004;10 Suppl 1():S35-7.
2004: William J Sandborn
How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Reviews in gastroenterological disorders 2004;4 Suppl 3():S25-33.
2004: William J Sandborn
Serologic markers in inflammatory bowel disease: state of the art.
Reviews in gastroenterological disorders 2004;4(4):167-74.
2004: Carlton W Thomas; Brian G Weinshenker; William J Sandborn
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
Inflammatory bowel diseases 2004;10(1):28-31.
2004: Jean-Frédéric Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
Gastroenterology 2004;126(1):19-31.
2004: Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Venous thromboembolism in inflammatory bowel disease.
The American journal of gastroenterology 2004;99(1):97-101.
2003: William J Sandborn
Evidence-based treatment algorithm for mild to moderate Crohn's disease.
The American journal of gastroenterology 2003;98(12 Suppl):S1-5.
2003: William J Sandborn
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.
Current gastroenterology reports 2003;5(6):501-5.
2003: Edward V Loftus; Sara J Achenbach; William J Sandborn; William J Tremaine; Ann L Oberg; Joseph L Melton
Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2003;1(6):465-73.
2003: William J Sandborn; Ted A Yednock
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
The American journal of gastroenterology 2003;98(11):2372-82.
2003: William J Sandborn; Victor W Fazio; Brian G Feagan; Stephen B Hanauer
AGA technical review on perianal Crohn's disease.
Gastroenterology 2003;125(5):1508-30.
2003: Jean-Frédéric Colombel; Elena Ricart; Edward V Loftus; William J Tremaine; Tonia M Young-Fadok; Eric J Dozois; Bruce G Wolff; Richard M Devine; John H Pemberton; William J Sandborn
Management of Crohn's disease of the ileoanal pouch with infliximab.
The American journal of gastroenterology 2003;98(10):2239-44.
2003: Peter B Wold; Joel G Fletcher; C Daniel Johnson; William J Sandborn
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study.
Radiology 2003;229(1):275-81.
2003: William J Sandborn; Brian G Feagan
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Alimentary pharmacology & therapeutics 2003;18(3):263-77.
2003: William J Sandborn; Daniel H Present; Kim L Isaacs; Douglas C Wolf; Eugene Greenberg; Stephen B Hanauer; Brian G Feagan; Lloyd Mayer; Therese Johnson; Joseph A Galanko; Christopher F Martin; Robert S Sandler
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.
Gastroenterology 2003;125(2):380-8.
2003: Carlton W Thomas; Philip W Lowry; Curtis L Franklin; Amy L Weaver; Gennett M Myhre; Dennis C Mays; William J Tremaine; James J Lipsky; William J Sandborn
Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
Inflammatory bowel diseases 2003;9(4):237-45.
2003: Sunanda V Kane; William J Sandborn; Paul A Rufo; Anna Zholudev; James Boone; David M Lyerly; Michael Camilleri; Stephen B Hanauer
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
The American journal of gastroenterology 2003;98(6):1309-14.
2003: William J Sandborn; Bruce Sands; D C Wolf; John Valentine; Michael A Safdi; S Katz; Kim L Isaacs; Lawrence Wruble; J Katz; Daniel H Present; E V Loftus; F Graeme-Cook; D J Odenheimer; Stephen B Hanauer
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Alimentary pharmacology & therapeutics 2003;17(11):1355-64.
2003: Charles O Elson; Ryan Sartor; Stephan R Targan; William J Sandborn
Challenges in IBD Research: updating the scientific agendas.
Inflammatory bowel diseases 2003;9(3):137-53.
2003: Uma Mahadevan; William J Sandborn
Diagnosis and management of pouchitis.
Gastroenterology 2003;124(6):1636-50.
2003: William J Sandborn
Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
Gastroenterology 2003;124(4):1140-5.
2003: William J Sandborn
Strategies for targeting tumour necrosis factor in IBD.
Best practice & research. Clinical gastroenterology 2003;17(1):105-17.
2003: Conor G Loftus; Edward V Loftus; William J Sandborn
Cyclosporin for refractory ulcerative colitis.
Gut 2003;52(2):172-3.
2003: William J Sandborn; Stephen B Hanauer
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Alimentary pharmacology & therapeutics 2003;17(1):29-42.
2002: William J Sandborn; Stephen B Hanauer
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
The American journal of gastroenterology 2002;97(12):2962-72.
2002: William J Sandborn
Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis.
The American journal of gastroenterology 2002;97(12):2939-41.
2002: Darrell S Pardi; Venktesh R Ramnath; Edward V Loftus; William J Tremaine; William J Sandborn
Lymphocytic colitis: clinical features, treatment, and outcomes.
The American journal of gastroenterology 2002;97(11):2829-33.
2002: Uma Mahadevan; Edward V Loftus; William J Tremaine; John H Pemberton; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn
Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications.
Inflammatory bowel diseases 2002;8(5):311-6.
2002: Craig A Solem; Edward V Loftus; William J Tremaine; John H Pemberton; Bruce G Wolff; William J Sandborn
Fistulas to the urinary system in Crohn's disease: clinical features and outcomes.
The American journal of gastroenterology 2002;97(9):2300-5.
2002: Sunanda V Kane; Philip Schoenfeld; William J Sandborn; W Tremaine; Timothy P Hofer; Brian G Feagan
The effectiveness of budesonide therapy for Crohn's disease.
Alimentary pharmacology & therapeutics 2002;16(8):1509-17.
2002: Edward V Loftus; Cynthia S Crowson; William J Sandborn; William J Tremaine; W Michael O'Fallon; Joseph L Melton
Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota.
Gastroenterology 2002;123(2):468-75.
2002: Elena Ricart; William R Taylor; Edward V Loftus; Dennis O'Kane; Richard M Weinshilboum; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
The American journal of gastroenterology 2002;97(7):1763-8.
2002: William J Sandborn; Stephan R Targan
Biologic therapy of inflammatory bowel disease.
Gastroenterology 2002;122(6):1592-608.
2002: Douglas L Riegert-Johnson; John A Godfrey; Jeffrey L Myers; Rolf D Hubmayr; William J Sandborn; Edward V Loftus
Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.
Inflammatory bowel diseases 2002;8(3):186-91.
2002: Thomas A Ullman; Edward V Loftus; Sanjay Kakar; Lawrence J Burgart; William J Sandborn; William J Tremaine
The fate of low grade dysplasia in ulcerative colitis.
The American journal of gastroenterology 2002;97(4):922-7.
2002: Uma Mahadevan; Edward V Loftus; William J Tremaine; William J Sandborn
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
The American journal of gastroenterology 2002;97(4):910-4.
2002: Darrell S Pardi; Thomas C Smyrk; William J Tremaine; William J Sandborn
Microscopic colitis: a review.
The American journal of gastroenterology 2002;97(4):794-802.
2002: David A Schwartz; Edward V Loftus; William J Tremaine; Remo Panaccione; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.
Gastroenterology 2002;122(4):875-80.
2002: Edward V Loftus; William J Sandborn
Epidemiology of inflammatory bowel disease.
Gastroenterology clinics of North America 2002;31(1):1-20.
2002: William J Sandborn; Brian G Feagan; Stephen B Hanauer; Herbert Lochs; Robert Löfberg; Robert Modigliani; Daniel H Present; Paul Rutgeerts; Jurgen Schölmerich; Eduard F Stange; Lloyd R Sutherland
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
Gastroenterology 2002;122(2):512-30.
2002: Brian G Feagan; William J Sandborn
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Reviews in gastroenterological disorders 2002;2 Suppl 2():S9-15.
2002: Edward V Loftus; Philip Schoenfeld; William J Sandborn
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.
Alimentary pharmacology & therapeutics 2002;16(1):51-60.
2002: Gerald A Dayharsh; Edward V Loftus; William J Sandborn; William J Tremaine; Alan R Zinsmeister; Thomas E Witzig; William R Macon; Lawrence J Burgart
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
Gastroenterology 2002;122(1):72-7.
2001: Uma Mahadevan; William J Sandborn
Evolving medical therapies for Crohn's disease.
Current gastroenterology reports 2001;3(6):471-6.
2001: D A Schwartz; J H Pemberton; William J Sandborn
Diagnosis and treatment of perianal fistulas in Crohn disease.
Annals of internal medicine 2001;135(10):906-18.
2001: D A Schwartz; M J Wiersema; K M Dudiak; Joel G Fletcher; Jonathan E Clain; William J Tremaine; Alan R Zinsmeister; Ian D Norton; L A Boardman; Richard M Devine; Bruce G Wolff; Tonia M Young-Fadok; Nancy N Diehl; John H Pemberton; William J Sandborn
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas.
Gastroenterology 2001;121(5):1064-72.
2001: Philip W Lowry; Curtis L Franklin; Amy L Weaver; MG Pike; Dennis C Mays; William J Tremaine; James J Lipsky; William J Sandborn
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.
Gut 2001;49(5):665-70.
2001: Philip W Lowry; Curtis L Franklin; Amy L Weaver; Carol L Szumlanski; Dennis C Mays; E V Loftus; William J Tremaine; James J Lipsky; Richard M Weinshilboum; William J Sandborn
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
Gut 2001;49(5):656-64.
2001: William A Faubion; E V Loftus; William J Sandborn; Deborah K Freese; Jean Perrault
Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc.
Journal of pediatric gastroenterology and nutrition 2001;33(3):296-300.
2001: William J Sandborn; E V Loftus; J F Colombel; K A Fleming; F Seibold; H A Homburger; Boualem Sendid; R W Chapman; W J Tremaine; D K Kaul; J Wallace; W S Harmsen; Alan R Zinsmeister; S R Targan
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
Inflammatory bowel diseases 2001;7(3):192-201.
2001: William J Tremaine; William J Sandborn; Edward V Loftus; M L Kenan; Tanya M Petterson; Alan R Zinsmeister; Marc D Silverstein
A prospective cohort study of practice guidelines in inflammatory bowel disease.
The American journal of gastroenterology 2001;96(8):2401-6.
2001: A H Patel; Edward V Loftus; Joseph A Murray; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Cigarette smoking and celiac sprue: a case-control study.
The American journal of gastroenterology 2001;96(8):2388-91.
2001: William A Faubion; Edward V Loftus; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.
Gastroenterology 2001;121(2):255-60.
2001: MG Pike; Curtis L Franklin; Dennis C Mays; James J Lipsky; Philip W Lowry; William J Sandborn
Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood.
Journal of chromatography. B, Biomedical sciences and applications 2001;757(1):1-9.
2001: G A Decker; Edward V Loftus; T M Pasha; William J Tremaine; William J Sandborn
Crohn's disease of the esophagus: clinical features and outcomes.
Inflammatory bowel diseases 2001;7(2):113-9.
2001: William J Sandborn
Transcending conventional therapies: the role of biologic and other novel therapies.
Inflammatory bowel diseases 2001;7 Suppl 1():S9-16.
2001: AM Levy; K Yamazaki; V P Van Keulen; Lawrence J Burgart; William J Sandborn; Sidney F Phillips; Gail M Kephart; Gerald J Gleich; Kristin M Leiferman
Increased eosinophil infiltration and degranulation in colonic tissue from patients with collagenous colitis.
The American journal of gastroenterology 2001;96(5):1522-8.
2001: Darrell S Pardi; Edward V Loftus; William J Tremaine; William J Sandborn
Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine.
Gastroenterology 2001;120(6):1483-4.
2001: William J Sandborn; Brian G Feagan; Stephen B Hanauer; Daniel H Present; L R Sutherland; M A Kamm; D C Wolf; J P Baker; C Hawkey; A Archambault; C N Bernstein; C Novak; P K Heath; S R Targan
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Gastroenterology 2001;120(6):1330-8.
2001: William J Sandborn
Rational dosing of azathioprine and 6-mercaptopurine.
Gut 2001;48(5):591-2.
2001: William J Sandborn
Cyclosporine in ulcerative colitis: state of the art.
Acta gastro-enterologica Belgica 2001;64(2):201-4.
2001: William J Sandborn
Strategies targeting tumor necrosis factor in Crohn's disease.
Acta gastro-enterologica Belgica 2001;64(2):170-2.
2001: Elena Ricart; Remo Panaccione; Edward V Loftus; William J Tremaine; William J Sandborn
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
The American journal of gastroenterology 2001;96(3):722-9.
2001: Stephen B Hanauer; William J Sandborn
Management of Crohn's disease in adults.
The American journal of gastroenterology 2001;96(3):635-43.
2001: Uma Mahadevan; William J Sandborn
Infliximab for the treatment of orofacial Crohn's disease.
Inflammatory bowel diseases 2001;7(1):38-42.
2000: Uma Mahadevan; William J Tremaine; T Johnson; MG Pike; Dennis C Mays; James J Lipsky; William J Sandborn
Intravenous azathioprine in severe ulcerative colitis: a pilot study.
The American journal of gastroenterology 2000;95(12):3463-8.
2000: William J Sandborn; William A Faubion
Clinical pharmacology of inflammatory bowel disease therapies.
Current gastroenterology reports 2000;2(6):440-5.
2000: Laurence J Egan; William J Tremaine; Dennis C Mays; James J Lipsky; William J Sandborn
Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease.
Inflammatory bowel diseases 2000;6(4):286-9.
2000: Paul J Limburg; David A Ahlquist; William J Sandborn; Douglas W Mahoney; M E Devens; Jonathan J Harrington; Alan R Zinsmeister
Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy.
The American journal of gastroenterology 2000;95(10):2831-7.
2000: William J Sandborn
Steroid-dependent Crohn's disease.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2000;14 Suppl C():17C-22C.
2000: Edward V Loftus; William J Tremaine; T M Habermann; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Risk of lymphoma in inflammatory bowel disease.
The American journal of gastroenterology 2000;95(9):2308-12.
2000: William J Sandborn
Therapy for Crohn disease.
Current opinion in gastroenterology 2000;16(4):318-23.
2000: Darrell S Pardi; William J Tremaine; William J Sandborn; Edward V Loftus; Gregory A Poland; W Scott Harmsen; Alan R Zinsmeister; Joseph L Melton
Early measles virus infection is associated with the development of inflammatory bowel disease.
The American journal of gastroenterology 2000;95(6):1480-5.
2000: Edward V Loftus; Marc D Silverstein; William J Sandborn; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.
Gut 2000;46(3):336-43.
1999: Laurence J Egan; William J Sandborn; William J Tremaine; Jonathan A Leighton; Dennis C Mays; MG Pike; Alan R Zinsmeister; James J Lipsky
A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis.
Alimentary pharmacology & therapeutics 1999;13(12):1597-604.
1999: P W Lowry; A L Weaver; William J Tremaine; William J Sandborn
Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae.
Inflammatory bowel diseases 1999;5(4):239-45.
1999: Laurence J Egan; Dennis C Mays; Catherine J Huntoon; Michael P Bell; MG Pike; William J Sandborn; James J Lipsky; David J McKean
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity.
The Journal of biological chemistry 1999;274(37):26448-53.
1999: William J Sandborn; William J Tremaine; D C Wolf; Stephan R Targan; C A Sninsky; L R Sutherland; Stephen B Hanauer; J W McDonald; Brian G Feagan; Richard N Fedorak; Kim L Isaacs; MG Pike; Dennis C Mays; James J Lipsky; S Gordon; CS Kleoudis; RH Murdock
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.
Gastroenterology 1999;117(3):527-35.
1999: Laurence J Egan; William J Sandborn; Dennis C Mays; William J Tremaine; James J Lipsky
Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate.
Inflammatory bowel diseases 1999;5(3):167-73.
1999: Elena Ricart; Remo Panaccione; Edward V Loftus; William J Tremaine; William J Sandborn
Successful management of Crohn's disease of the ileoanal pouch with infliximab.
Gastroenterology 1999;117(2):429-32.
1999: P W Lowry; William J Sandborn; James J Lipsky
Mycophenolate mofetil for Crohn's disease?
Lancet 1999;354(9172):3-4.
1999: R Panaccione; William J Sandborn
The appendix in ulcerative colitis: a not so innocent bystander.
Gastroenterology 1999;117(1):272-3.
1999: Philip W Lowry; Carol L Szumlanski; Richard M Weinshilboum; William J Sandborn
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.
Gastroenterology 1999;116(6):1505-6.
1999: William J Sandborn; Stephen B Hanauer
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
Inflammatory bowel diseases 1999;5(2):119-33.
1999: Darrell S Pardi; William J Tremaine; William J Sandborn; Edward V Loftus; Gregory A Poland; Joseph L Melton
Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease.
Inflammatory bowel diseases 1999;5(2):104-6.
1999: William J Tremaine; William J Sandborn
Practice guidelines for inflammatory bowel disease: an instrument for assessment.
Mayo Clinic proceedings. Mayo Clinic 1999;74(5):495-501.
1999: William J Sandborn
Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results.
The American journal of gastroenterology 1999;94(5):1161-71.
1999: P W Lowry; William J Sandborn
A comparison of budesonide and mesalamine for active Crohn's disease.
Gastroenterology 1999;116(5):1263.
1999: R Panaccione; William J Sandborn
Is antibody testing for inflammatory bowel disease clinically useful?
Gastroenterology 1999;116(4):1001-2; discussion 1002-3.
1999: Paul Angulo; A E Bharucha; Roberta Jorgensen; CK DeSotel; William J Sandborn; Nicholas F LaRusso; Keith D Lindor
Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study.
Digestive diseases and sciences 1999;44(3):602-7.
1999: William J Sandborn; R McLeod; D P Jewell
Medical therapy for induction and maintenance of remission in pouchitis: a systematic review.
Inflammatory bowel diseases 1999;5(1):33-9.
1999: M Muñoz-Juarez; John H Pemberton; William J Sandborn; William J Tremaine; Roger R Dozois
Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases.
Diseases of the colon and rectum 1999;42(1):117-20.
1999: Eric L Matteson; C H Orces; J Duffy; James J Lipsky; MG Pike; William J Sandborn
Induction therapy with an intravenous loading dose of azathioprine for treatment of refractory, active rheumatoid arthritis.
Arthritis and rheumatism 1999;42(1):186-7.
1998: Laurence J Egan; William J Sandborn
Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy?
Gastroenterology 1998;115(5):1295-6.
1998: Laurence J Egan; William J Sandborn; Dennis C Mays; William J Tremaine; James J Lipsky
Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision.
Alimentary pharmacology & therapeutics 1998;12(7):679-84.
1998: Edward V Loftus; M D Silverstein; William J Sandborn; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.
Gastroenterology 1998;114(6):1161-8.
1998: Laurence J Egan; William J Sandborn
Drug therapy of inflammatory bowel disease.
Drugs of today (Barcelona, Spain : 1998) 1998;34(5):431-46.
1998: Darrell S Pardi; William J Tremaine; William J Sandborn; James T McCarthy
Renal and urologic complications of inflammatory bowel disease.
The American journal of gastroenterology 1998;93(4):504-14.
1998: A G Kaditis; Jean Perrault; William J Sandborn; C J Landers; Alan R Zinsmeister; Stephan R Targan
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis.
Journal of pediatric gastroenterology and nutrition 1998;26(4):386-92.
1998: Laurence J Egan; William J Sandborn; William J Tremaine
Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
The American journal of gastroenterology 1998;93(3):442-8.
1998: Edward V Loftus; H I Aguilar; William J Sandborn; William J Tremaine; Ruud A F Krom; Alan R Zinsmeister; Ivo W Graziadei; Russell H Wiesner
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation.
Hepatology (Baltimore, Md.) 1998;27(3):685-90.
1998: K W Nuako; D A Ahlquist; William J Sandborn; D W Mahoney; D M Siems; Alan R Zinsmeister
Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study.
Cancer 1998;82(5):822-6.
1997: William J Tremaine; William J Sandborn; Bruce G Wolff; H A Carpenter; Alan R Zinsmeister; P P Metzger
Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial.
Alimentary pharmacology & therapeutics 1997;11(6):1041-6.
1997: RF Compton; William J Sandborn; GM Lawson; A J Sheets; Dennis C Mays; BJ Zins; William J Tremaine; James J Lipsky; DW Mahoney; Alan R Zinsmeister; KP Offord; RD Hurt; B K Evans; J Green
A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration.
Alimentary pharmacology & therapeutics 1997;11(5):865-74.
1997: William J Sandborn; William J Tremaine; Jonathan A Leighton; GM Lawson; BJ Zins; RF Compton; Dennis C Mays; James J Lipsky; K P Batts; KP Offord; RD Hurt; J Green
Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study.
Alimentary pharmacology & therapeutics 1997;11(4):663-71.
1997: DC Nyam; John H Pemberton; William J Sandborn; M Savcenko
Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a case.
Diseases of the colon and rectum 1997;40(8):971-2.
1997: EV Loftus; William J Tremaine; R A Nelson; J D Shoemaker; William J Sandborn; Sidney F Phillips; Y Hasan
Dexpanthenol enemas in ulcerative colitis: a pilot study.
Mayo Clinic proceedings. Mayo Clinic 1997;72(7):616-20.
1997: BJ Zins; William J Sandborn; Dennis C Mays; GM Lawson; J A McKinney; William J Tremaine; DW Mahoney; Alan R Zinsmeister; RD Hurt; KP Offord; James J Lipsky
Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration.
Journal of clinical pharmacology 1997;37(5):426-36.
1997: William J Sandborn
Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
The American journal of gastroenterology 1997;92(5):876-9.
1997: William J Sandborn; William J Tremaine; KP Offord; GM Lawson; B T Petersen; K P Batts; Ivana T Croghan; LC Dale; DR Schroeder; RD Hurt
Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial.
Annals of internal medicine 1997;126(5):364-71.
1997: AM Levy; Gerald J Gleich; William J Sandborn; William J Tremaine; B L Steiner; Sidney F Phillips
Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease.
Mayo Clinic proceedings. Mayo Clinic 1997;72(2):117-23.
1997: Edward V Loftus; William J Sandborn; Keith D Lindor; N F Larusso
Interactions between chronic liver disease and inflammatory bowel disease.
Inflammatory bowel diseases 1997;3(4):288-302.
1997: William J Sandborn
Does the surgical failure rate, increased incidence of pouchitis, and recent findings of dysplasia in pouches deter you from recommending an ileal pouch-anal anastomosis for ulcerative colitis?
Inflammatory bowel diseases 1997;3(3):239-40.
1997: BJ Zins; William J Sandborn; J A McKinney; Dennis C Mays; EC van Os; William J Tremaine; DW Mahoney; Alan R Zinsmeister; James J Lipsky
A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation.
Journal of clinical pharmacology 1997;37(1):38-46.
1997: RF Compton; William J Sandborn; Huiying Yang; Noralane M Lindor; William J Tremaine; M D Davis; A A Khalil; Nikolaos A Tountas; Dolly Tyan; Carol J Landers; Kent D Taylor; T R Viggiano; E L Matteson; A L Schroeter; Scott Plevy; Fabio Cominelli; Stephan R Targan; Jerome I Rotter
A new syndrome of Crohn's disease and pachydermoperiostosis in a family.
Gastroenterology 1997;112(1):241-9.
1996: E C Van Os; BJ Zins; William J Sandborn; Dennis C Mays; William J Tremaine; Douglas W Mahoney; Alan R Zinsmeister; James J Lipsky
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
Gut 1996;39(1):63-8.
1996: William J Sandborn; Carol J Landers; William J Tremaine; Stephan R Targan
Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study.
Mayo Clinic proceedings. Mayo Clinic 1996;71(5):431-6.
1996: Edward V Loftus; William J Sandborn; William J Tremaine; Douglas W Mahoney; Alan R Zinsmeister; K P Offord; Joseph L Melton
Primary sclerosing cholangitis is associated with nonsmoking: a case-control study.
Gastroenterology 1996;110(5):1496-502.
1996: E C Van Os; J A McKinney; BJ Zins; Dennis C Mays; Z H Schriver; William J Sandborn; James J Lipsky
Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;679(1-2):147-54.
1996: William J Sandborn
A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
The American journal of gastroenterology 1996;91(3):423-33.
1996: C Penna; Roger R Dozois; William J Tremaine; William J Sandborn; Nicholas F LaRusso; C Schleck; D Ilstrup
Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.
Gut 1996;38(2):234-9.
1996: Edward V Loftus; William J Sandborn; William J Tremaine; Douglas W Mahoney; Alan R Zinsmeister; K P Offord; Joseph L Melton
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis.
Gastroenterology 1996;110(2):432-40.
1996: William J Sandborn; William J Tremaine; GM Lawson
Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine.
The American journal of gastroenterology 1996;91(1):37-43.
1996: Laurence J Egan; William J Sandborn
Methotrexate for inflammatory bowel disease: pharmacology and preliminary results.
Mayo Clinic proceedings. Mayo Clinic 1996;71(1):69-80.
1995: BJ Zins; William J Sandborn; C R Penna; Carol J Landers; Stephan R Targan; William J Tremaine; R H Wiesner; R R Dozois
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis.
The American journal of gastroenterology 1995;90(12):2177-81.
1995: William J Sandborn; E C Van O; BJ Zins; William J Tremaine; Dennis C Mays; James J Lipsky
An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.
Gastroenterology 1995;109(6):1808-17.
1995: BJ Zins; William J Sandborn; William J Tremaine
Collagenous and lymphocytic colitis: subject review and therapeutic alternatives.
The American journal of gastroenterology 1995;90(9):1394-400.
1995: William J Sandborn; William J Tremaine; Kenneth P Batts; J H Pemberton; S S Rossi; A F Hofmann; G J Gores; S F Phillips
Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis.
Digestive diseases and sciences 1995;40(7):1474-83.
1995: William J Sandborn; Carol J Landers; William J Tremaine; Stephan R Targan
Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis.
The American journal of gastroenterology 1995;90(5):740-7.
1995: William J Sandborn; G M Lawson; T J Cody; Michael K Porayko; J Eileen Hay; Gregory J Gores; Jeffery L Steers; Ruud A F Krom; Russell H Wiesner
Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue.
Hepatology (Baltimore, Md.) 1995;21(1):70-6.
1994: William J Sandborn
Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment.
Gastroenterology 1994;107(6):1856-60.
1994: William J Sandborn; William J Tremaine; K W Schroeder; Kenneth P Batts; GM Lawson; B L Steiner; J M Harrison; Alan R Zinsmeister
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis.
Gastroenterology 1994;106(6):1429-35.
1994: William J Sandborn; William J Tremaine; Kenneth P Batts; J H Pemberton; S F Phillips
Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index.
Mayo Clinic proceedings. Mayo Clinic 1994;69(5):409-15.
1994: William J Sandborn; J Eileen Hay; Michael K Porayko; Gregory J Gores; Jeffery L Steers; Ruud A F Krom; Russell H Wiesner
Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection.
Hepatology (Baltimore, Md.) 1994;19(4):925-32.
1993: William J Sandborn; William J Tremaine; K W Schroeder; B L Steiner; Kenneth P Batts; GM Lawson
Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis.
The American journal of gastroenterology 1993;88(5):640-5.
1993: William J Sandborn; Russell H Wiesner; William J Tremaine; Nicholas F LaRusso
Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.
Gut 1993;34(2):242-6.
1992: William J Sandborn; William J Tremaine
Cyclosporine treatment of inflammatory bowel disease.
Mayo Clinic proceedings. Mayo Clinic 1992;67(10):981-90.
1992: William J Sandborn; G M Lawson; Ruud A F Krom; Russell H Wiesner
Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection.
Hepatology (Baltimore, Md.) 1992;15(6):1086-91.